Analysts expect over 2018 rising revenue Pharming

Over the current book year the total revenue will be 136,67 million euros (consensus estimates). This is rather significant more than 2017's revenue of 89,62 million euros.

Historical revenues and results Pharming plus estimates 2018

historical stocks

The analysts expect for 2018 a net profit of 24 million euros. The majority of the analysts expects for this year a profit per share of 4 cent. Based on this the price/earnings-ratio is 20,75.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,5 percent.

Newest target prices around 2 euros

The latest 3 recommendations for the biotech company were provided by Stifel, Beleggers Belangen and Beursexpres.

Pharming's market value equals around 377,68 million . The Pharming stock was the past 12 months quite volatile. Since last January the stock is 45 percent lower. This year the stock price moved between 1 and 2 euro. Since 2008 the stock price is almost 83 percent lower.

Price data Pharming 2007-2018

historical stocks pharming

At 13.15 the stock trades 1,21 percent lower at 0,83 euros. News Wire & Equity Research: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.